ESR1 and breast cancer: The validation step assessed the associations between the presence of loss-of-function (LoF) and rare missense variants in 198 selected candidate genes and the risk of breast cancer overall, as well as estrogen receptor (ER) disease subtypes, in a replication set of 6211 breast cancer cases and 6019 controls.